Flare Therapeutics Presents Data at AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cell Patterns in Urothelial Cancer Patients After Anti-PD1 Therapy
Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium
--First-in-human trial evaluating safety, tolerability, and clinical activity of FX-909 in patients with advanced solid malignancies including advanced urothelial carcinoma--
Flare Therapeutics Presents New Translational Data in Support of Lead Asset FX-909 for the Treatment of Muscle-Invasive Urothelial Cancer at SITC 2023 Annual Meeting
--Poster presentation proposes targeting PPARG for the treatment of muscle-invasive urothelial cancer (MIUC) may help overcome resistance to immunotherapy--
Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer
FX-909 is a first-in-class small molecule inhibitor of the PPARG transcription factor for the potential treatment of advanced urothelial carcinoma
Flare Therapeutics Presents Novel, AI-Based Method Identifying Luminal Subtype of Urothelial Cancer Supporting Lead Asset FX-909 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer, at the 2023 AACR Annual Meeting
Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions
Michael L. Meyers, M.D., Ph.D. to join as Chief Medical Officer; Daphne Karydas promoted to President and Chief Financial Officer; Michaela Bowden, Ph.D., promoted to Chief Development Officer; and Jigar Raythatha joins the Board of Directors
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Led by GordonMD® Global Investments LP and Pfizer Ventures, financing to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare’s platform and pipeline of novel transcription factor targets in oncology
Flare Therapeutics to Present Overview of Clinical Candidate FX-909 at AACR Annual Meeting
Robert Sims, Ph.D., Chief Scientific Officer and co-founder of Flare Therapeutics, will present the discovery of its clinical candidate, FX-909, at the AACR Annual Meeting in Orlando, FL
Flare Therapeutics to Present at Guggenheim Healthcare Talks Oncology Day
Robert Sims, Ph.D., Chief Scientific Officer and co-founder at Flare Therapeutics, will present a company overview at the upcoming Guggenheim Healthcare Talks Oncology Day in New York, NY
Flare Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
Daphne Karydas, Chief Operating Officer and Chief Financial Officer of Flare Therapeutics, will present a company overview at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NY
Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium
Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approach
Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors
Company has pioneered ‘switch site’ approach to uncover druggable regions within well validated, but elusive, transcription factors that are master regulators of gene expression
